Hangzhou Tigermed Consulting Co., Ltd Fundamental Analysis
Hangzhou Tigermed Consulting Co., Ltd (3347.HK) shows weak financial fundamentals with a PE ratio of 32.71, profit margin of 10.91%, and ROE of 3.69%. The company generates $10.5B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 54.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 3347.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak3347.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate3347.HK shows balanced valuation metrics.
Growth Score
Moderate3347.HK shows steady but slowing expansion.
Financial Health Score
Excellent3347.HK maintains a strong and stable balance sheet.
Profitability Score
Weak3347.HK struggles to sustain strong margins.
Key Financial Metrics
Is 3347.HK Expensive or Cheap?
P/E Ratio
3347.HK trades at 32.71 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 3347.HK's PEG of 0.32 indicates potential undervaluation.
Price to Book
The market values Hangzhou Tigermed Consulting Co., Ltd at 1.15 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 19.91 times EBITDA. This signals the market has high growth expectations.
How Well Does 3347.HK Make Money?
Net Profit Margin
For every $100 in sales, Hangzhou Tigermed Consulting Co., Ltd keeps $10.91 as profit after all expenses.
Operating Margin
Core operations generate 17.97 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.69 in profit for every $100 of shareholder equity.
ROA
Hangzhou Tigermed Consulting Co., Ltd generates $2.68 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Hangzhou Tigermed Consulting Co., Ltd produces operating cash flow of $2.06B, showing steady but balanced cash generation.
Free Cash Flow
Hangzhou Tigermed Consulting Co., Ltd generates strong free cash flow of $1.74B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.43 in free cash annually.
FCF Yield
3347.HK converts 3.27% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
32.71
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.32
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.15
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.05
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.07
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.30
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How 3347.HK Stacks Against Its Sector Peers
| Metric | 3347.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 32.71 | 29.63 | Worse (Expensive) |
| ROE | 3.69% | 223.00% | Weak |
| Net Margin | 10.91% | -38669.00% (disorted) | Strong |
| Debt/Equity | 0.07 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 2.30 | 4.30 | Strong Liquidity |
| ROA | 2.68% | -379.00% (disorted) | Weak |
3347.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Hangzhou Tigermed Consulting Co., Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation